System-Wide Proteomic Remodeling in Spinal Muscular Atrophy Reveals Tissue-Specific Responses and Partial Rescue by SMN Restoration

This study reveals that SMN deficiency in Spinal Muscular Atrophy drives extensive, tissue-specific proteomic remodeling across multiple organs, with partial SMN restoration via antisense oligonucleotides only incompletely reversing these molecular alterations, particularly in metabolic and mitochondrial pathways.

The Gist

The Big Picture: A City in Trouble

Imagine the human body as a massive, bustling city. In this city, there is a very important manager named SMN (Survival Motor Neuron). This manager's job is to keep the lights on, the trash collected, and the construction crews working smoothly in every single building, from the central government (the brain/spinal cord) to the power plants (the heart) and the factories (the muscles).

Spinal Muscular Atrophy (SMA) is a disease where the city runs out of this manager. Without enough SMN, the city starts to fall apart. For a long time, doctors thought only the "government buildings" (the nerves controlling movement) were in trouble. But this new study shows that the whole city is suffering, not just the government.

The Experiment: A Partial Fix

The researchers took a look at three specific districts in a mouse model of this disease:

1. The Spinal Cord (The Central Command)
2. The Heart (The Power Plant)
3. The Leg Muscle (The Factory)

They wanted to see what happens when they try to fix the city by bringing in a "substitute manager" (using a drug called an ASO) to replace the missing SMN. Crucially, they didn't bring in enough to fix everything perfectly; they brought in just enough to see if a partial fix helps.

What They Found: The City is Different in Every District

1. The Damage Looks Different Everywhere
When the manager (SMN) is missing, the city doesn't break down in the same way everywhere.

• The Central Command (Spinal Cord): It's messy, but the damage is somewhat contained.
• The Power Plant (Heart) and Factory (Muscle): These places are in chaos! The researchers found that the muscles and heart had much more widespread damage than the spinal cord. It's like the factory floor is covered in debris, while the office just has a few papers scattered on the desk.
• The Analogy: If the city were a house, the spinal cord is the living room (a bit messy), but the heart and muscles are the kitchen and garage (completely trashed).

2. The "Substitute Manager" Only Fixes Some Rooms
The researchers gave the mice the drug to bring back some SMN. They hoped the city would go back to normal.

• The Good News: The drug worked! In many areas, the mess started to get cleaned up. The "substitute manager" helped fix the trash collection and the construction crews in specific departments.
• The Bad News: The fix was incomplete. Even with the drug, some parts of the city remained broken.
• The "Stuck" Problem: The most stubborn damage was in the energy systems (mitochondria). Think of mitochondria as the city's power generators. Even after the drug was given, the power generators in the heart and spinal cord were still sputtering and failing. The drug couldn't fully restart the engines that had already stalled.

3. You Can't Un-Crumple a Paper
The study suggests that once the city has been in a state of chaos for too long (the "symptomatic stage"), some of the damage becomes permanent or very hard to reverse.

• The Analogy: Imagine you crumple a piece of paper (the cell). If you smooth it out immediately, it looks fine. But if you leave it crumpled for a while, the creases stay. The drug smoothed out the paper, but the deep creases (the metabolic and mitochondrial damage) remained visible.

The Takeaway for Patients and Families

This study teaches us two very important lessons:

1. SMA is a Whole-Body Disease: We can't just focus on the nerves. The heart and muscles are deeply affected, and they need their own specific care.
2. Early is Better, but "Partial" isn't "Perfect": The drug (ASO) is a miracle because it stops the bleeding and cleans up a lot of the mess. However, because the damage to the energy systems was so deep, the drug couldn't fix everything 100%.

The Bottom Line:
Think of the drug as a heroic firefighter. They arrived and put out the biggest fires (saving the patient's life and improving movement). But the smoke damage (the metabolic issues) is still lingering in the walls. To get the city fully healthy again, we might need more than just one firefighter. We might need a team that includes a "power plant repair crew" to fix the energy systems that the first drug couldn't reach.

This research helps scientists understand why some patients don't get 100% better and points the way toward future treatments that combine the current drugs with new therapies to fix the stubborn energy problems.

Technical Summary

1. Problem Statement

Spinal Muscular Atrophy (SMA) is traditionally viewed as a neuromuscular disorder caused by the deficiency of the Survival Motor Neuron (SMN) protein, leading to the degeneration of lower motor neurons. However, emerging evidence suggests SMA is a multi-organ systemic disease. While SMN is ubiquitously expressed, different tissues exhibit varying degrees of vulnerability and distinct molecular responses to SMN deficiency.

• The Gap: Previous studies have largely focused on single organs or transcriptomic levels. There is a lack of a unified, unbiased proteomic atlas comparing central (spinal cord) and peripheral (heart, skeletal muscle) tissues within the same experimental framework.
• The Therapeutic Question: While SMN-restoring therapies (e.g., Antisense Oligonucleotides, ASOs) have improved clinical outcomes, it remains unclear whether early treatment fully normalizes tissue proteomes or if specific molecular alterations (particularly in metabolism) persist despite partial SMN restoration.

2. Methodology

The study employed a label-free quantitative proteomics approach using a severe SMA mouse model.

• Animal Model:
  • Genotypes: Wild-type (WT), Heterozygous (HET), and Severe SMA mice (Smn−/−; SMN2tg/0).
  • Treatment: Neonatal SMA mice received a single systemic subcutaneous injection of a splice-modulating SMN-ASO at Postnatal Day 1 (P1) to induce partial SMN restoration. Control groups included untreated WT, HET, and SMA mice.
  • Sampling: Tissues (Spinal Cord, Heart, Gastrocnemius muscle) were collected at the symptomatic stage (P10).
• Proteomics Workflow:
  • Sample Prep: Urea-based protein extraction, reduction, alkylation, and sequential digestion (Lys-C and Trypsin).
  • Mass Spectrometry: Data-Independent Acquisition (DIA) using a Thermo Orbitrap Exploris 480 coupled with a FAIMS Pro interface.
  • Data Processing: Analysis via DIA-NN (v1.8.1) against a Mus musculus UniProt library, filtered at 1% False Discovery Rate (FDR).
• Bioinformatics & Statistical Analysis:
  • Tools: Perseus (statistical analysis), STRING (network analysis), Cytoscape/ClueGO (functional enrichment).
  • Stratification: Due to heterogeneity in the treated SMA group, samples were stratified via Principal Component Analysis (PCA) to focus on those showing the clearest shift toward the WT proteomic state.
  • Classification: Proteins were categorized based on their response to ASO treatment:
    1. Rescued: Shifted directionally toward WT levels.
    2. Persistent: Remained dysregulated without directional reversal.
    3. No Change/ASO-Responsive Only: No significant change or changes not present in baseline SMA.

3. Key Contributions

• First Cross-Tissue Proteomic Atlas: Generated a comprehensive, quantitative proteomic map of the spinal cord, heart, and skeletal muscle in SMA, revealing that peripheral tissues undergo broader molecular remodeling than the spinal cord.
• Quantification of Partial Rescue: Systematically defined the extent to which early, partial SMN restoration can reverse established proteomic alterations, demonstrating that rescue is tissue-dependent and incomplete.
• Identification of Persistent Pathways: Highlighted that mitochondrial and metabolic pathways remain dysregulated even after SMN elevation, suggesting these are hard-to-reverse secondary adaptations.

4. Key Results

A. Tissue-Specific Proteome Remodeling in SMA

• Extent of Dysregulation: Peripheral tissues (Heart and Gastrocnemius) exhibited significantly broader proteome alterations compared to the spinal cord.
  • Spinal Cord: Limited number of differentially abundant proteins; changes primarily involved membrane, nuclear, and mitochondrial components.
  • Heart & Muscle: Widespread alterations involving metabolic, mitochondrial, and cytoskeletal pathways.
• Overlap: There was limited overlap between the spinal cord and peripheral tissues. However, the heart and gastrocnemius showed convergence in metabolic and mitochondrial-associated pathways.
• Cellular Architecture: Downregulated proteins in SMA formed tissue-specific networks:
  • Spinal Cord: Axonogenesis, glial differentiation, ER/Golgi, and mitochondria.
  • Heart: DNA repair, intracellular trafficking, and clathrin-mediated endocytosis.
  • Muscle: Phospholipid efflux, mRNA processing, and neuromuscular junction development.

B. Response to SMN-ASO Treatment

• Partial Repositioning: PCA showed that ASO-treated SMA samples shifted toward the WT/HET cluster, but the shift was incomplete. No tissue fully returned to a WT proteomic state.
• Heterogeneous Rescue:
  • Rescued Pathways: Included immune-related processes (spinal cord), vesicle transport/cytoskeletal organization (heart), and synaptic/neuromuscular junction pathways (muscle).
  • Persistent Pathways: A substantial subset of proteins remained dysregulated. Crucially, mitochondrial respiratory chain and oxidative phosphorylation pathways were persistently downregulated in both the spinal cord and heart.
• Metabolic Resistance: The persistence of mitochondrial dysfunction suggests that once established, secondary metabolic adaptations are not fully reversible by partial SMN restoration alone, particularly at the symptomatic stage.

5. Significance and Implications

• Systemic Nature of SMA: The study confirms that SMA is a systemic disease where peripheral organs suffer profound, distinct proteomic consequences that are not merely secondary to denervation.
• Therapeutic Limitations: The findings explain why clinical benefits of SMN therapies can be variable. While early treatment is crucial, partial SMN restoration is insufficient to fully normalize the proteome, especially regarding metabolic and mitochondrial health.
• Future Directions: The persistence of mitochondrial and redox-related dysregulation despite treatment supports the hypothesis that combinatorial therapeutic strategies (e.g., SMN restoration + metabolic support or mitochondrial protectors) may be necessary to achieve full disease modification.
• Biomarker Potential: The identification of tissue-specific signatures provides a framework for developing biomarkers that monitor not just SMN levels, but the functional recovery of specific organ systems.

In conclusion, this study provides a high-resolution view of the SMA proteome, demonstrating that while SMN restoration initiates molecular correction, the disease leaves a "molecular scar" in the form of persistent mitochondrial and metabolic dysfunction that requires targeted intervention beyond SMN elevation alone.